In this informative video, we dive into one of the most pressing questions manufacturers have about FDA inspections: How often will the FDA come to inspect their facilities?

Our expert, Melissa Schneider, Associate Director of Compliance at Compliance Insight ([ Ссылка ]), sheds light on the inspection frequency and prioritization process. She explains that FDA inspections are scheduled on a yearly basis, with a focus on general Good Manufacturing Practice (GMP) inspections occurring approximately once every two years.

Melissa further reveals how the FDA determines which facilities to inspect and in what order, emphasizing that risk plays a crucial role. Factors such as previous inspection findings, critical issues, customer complaints, and the risk level of the products manufactured all influence inspection prioritization. Gain valuable insights to better understand the frequency and prioritization of FDA inspections for manufacturers by watching this video.

Watch the full interview with Melissa here: [ Ссылка ]

===============================

Visit us at [ Ссылка ]

Compliance Insight is a leading FDA regulatory and quality assurance consulting firm that offers a range of services to assist companies in navigating the complexities of FDA regulations. With their in-depth knowledge and expertise, Compliance Insight provides invaluable guidance and support to ensure compliance with FDA requirements.

One of their key services is assisting companies with the 510(k) process. They understand the intricacies involved in preparing and submitting 510(k) applications for medical devices. Compliance Insight helps clients gather the necessary data, conduct thorough reviews, and ensure the application meets all regulatory standards, streamlining the path to FDA clearance.

In addition, Compliance Insight has extensive experience in the emerging field of cell and gene therapies. They offer specialized guidance on navigating the unique regulatory landscape for these innovative therapies, helping clients understand and meet FDA requirements to bring their life-changing treatments to market.

Another area of expertise for Compliance Insight is providing assistance with 483 and Warning Letter response and remediation. In the event of an FDA inspection resulting in observations or deficiencies (captured in Form 483), Compliance Insight supports companies in developing comprehensive and effective responses. Their team works closely with clients to address each observation, develop appropriate corrective actions, and ensure timely and compliant resolution.

Whether it's navigating the 510(k) process, advancing cell and gene therapies, addressing 483 observations, product recalls, or more; Compliance Insight's services encompass comprehensive regulatory support to help companies achieve and maintain FDA compliance, fostering successful product development and market approval.

свернуть